Marbodin

Memantine, the active ingredient in Marbodin, is a NMDA receptor antagonist presented as a tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer's disease in adult patients. GNH USA supplies Marbodin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine is used in the management of neurodegenerative conditions affecting cognition, particularly within the Alzheimer’s disease spectrum. Alzheimer's disease (moderate): Improves cognitive function and daily living activities in patients with moderate disease severity. Alzheimer's disease (severe): Helps maintain functional abilities and may slow further decline in severe cases. Behavioral symptoms in Alzheimer's disease: May reduce agitation and improve overall patient behavior.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Hypertension - Insomnia

Serious or Rare Side Effects: - Seizures - Severe allergic reactions (rash, swelling, anaphylaxis) - Cardiac arrhythmias - Hepatic dysfunction (elevated liver enzymes) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal thoughts or behavior

Memantine should be used with caution in patients with certain medical conditions and in specific situations. Renal impairment: Adjust dose and monitor renal function. Hepatic impairment: Use with caution and monitor liver enzymes. History of seizures: May increase seizure risk; monitor closely. Concurrent use with other NMDA antagonists: Avoid additive neuro‑psychiatric effects. Pregnancy: Safety not established; weigh benefits against potential risks. Store at ambient temperature: Keep in original packaging, protect from moisture and direct light.

Memantine may interact with several medicines, requiring attention to avoid adverse outcomes. Major Interactions (Avoid): - Amantadine: Increased risk of neuropsychiatric side effects. - Ketamine: Additive NMDA antagonism may cause excessive CNS depression. - Other NMDA antagonists: Potential for severe neurotoxicity.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: May diminish cognitive benefits. - CNS depressants (e.g., benzodiazepines): May enhance dizziness and sedation. - Diuretics: May alter plasma concentrations of memantine. - Proton pump inhibitors: May affect drug absorption. - Antihypertensives: Possible additive effect on blood pressure.